REHOVOT, Israel, Aug. 19, 2014 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, announced today that Mr. Ofer Haviv, Evogene's President and CEO, will present at the Credit Suisse 2014 Basic Materials Conference taking place at the Credit Suisse Auditorium, located at One Madison Avenue in New York City, September 16-18, 2014. The presentation will take place on Thursday, September 18, at 11:45 am.
Investors or companies attending the conference, who wish to meet with Mr. Haviv, may contact Evogene's Investor Relations team at email@example.com.
About Evogene Ltd:
Evogene (NYSE:EVGN) (TASE:EVGN) is a leading company for the improvement of crop quality, productivity and economics for the food, feed and biofuel industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
CONTACT: Karen Mazor, Evogene Director, Public and Investor Relations T: +972-54-2288 039 firstname.lastname@example.org